Immunotherapy for metastatic renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Urologic clinics of North America

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 7684167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.

  1992cited by this paper
• Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.

  1992cited by this paper
• A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.

  1992cited by this paper
• Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.

  1992cited by this paper
• Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.

  1992cited by this paper
• Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha.

  1992cited by this paper
• Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma.

  1992cited by this paper
• Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.

  1991cited by this paper
• A phase II trial of interleukin‐2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma

  1991cited by this paper
• Atypical contrast reactions associated with systemic interleukin-2 therapy.

  1991cited by this paper
• Metastatic renal cell carcinoma treated with purified leukocyte interferon. Clinical response in relation to tumor DNA content.

  1991cited by this paper
• Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases.

  1991cited by this paper
• alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients.

  1991cited by this paper
• Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study.

  1991cited by this paper
• Recombinant alpha interferon in metastatic renal cell carcinoma. A cooperative phase II study.

  1991cited by this paper
• A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma.

  1991cited by this paper
• High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma.

  1990cited by this paper
• Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.

  1990cited by this paper
• Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.

  1990cited by this paper
• Cancer, cytokines, and cytotoxic cells: Interleukin-2 in the immunotherapy of human neoplasms

  1990cited by this paper
• Prediction of objective response to recombinant interferon-alpha with or without vinblastine in metastatic renal cell carcinoma.

  1990cited by this paper
• Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.

  1990cited by this paper
• Interleukin-2 therapy for advanced renal cell carcinoma: radiographic evaluation of response and complications.

  1990cited by this paper
• Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.

  1990cited by this paper
• Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma.

  1990cited by this paper
• Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma.

  1990cited by this paper
• Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma.

  1990cited by this paper
• Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial.

  1990cited by this paper
• Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.

  1989cited by this paper
• Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma.

  1989cited by this paper
• Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma.

  1989cited by this paper
• Role of interferons in the therapy of metastatic renal cell carcinoma.

  1989cited by this paper
• Treatment of renal cell carcinoma with daily low-dose alpha-interferon.

  1989cited by this paper
• Long-term interferon treatment in metastatic renal cell carcinoma.

  1989cited by this paper
• Cyclic interferon gamma treatment of patients with metastatic renal carcinoma.

  1989cited by this paper
• Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

  1989cited by this paper
• Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

  1989cited by this paper
• An assessment of the current use of human interferons in therapy of urological cancers.

  1989cited by this paper
• Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

  1989cited by this paper
• Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.

  1989cited by this paper
• The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin‐2: A Review

  1988cited by this paper
• [Treatment of metastatic kidney cancer with recombinant alpha-2 or gamma interferon. Results of 2 clinical phase II and III studies].

  1988cited by this paper
• Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

  1988cited by this paper
• Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma.

  1988cited by this paper
• Antitumor effects of human lymphoblastoid interferon on advanced renal cell carcinoma.

  1988cited by this paper
• Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

  1988cited by this paper
• Combination of recombinant interferon alpha‐2A and vinblastine in advanced renal cell cancer

  1988cited by this paper
• Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.

  1987cited by this paper
• High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.

  1987cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group.

  1987cited by this paper
• Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma.

  1987cited by this paper
• Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects.

  1987cited by this paper
• Interferon treatment of renal cell carcinoma. Current status and future prospects.

  1987cited by this paper
• Failure of immunotherapy for metastatic renal cell carcinoma.

  1986cited by this paper
• Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.

  1986cited by this paper
• Interferon therapy for the treatment of renal cancer

  1986cited by this paper
• Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.

  1986cited by this paper
• Recombinant interferon alfa‐2a with or without vinblastine in metastatic renal cell carcinoma

  1986cited by this paper
• A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.

  1986cited by this paper
• Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials

  1986cited by this paper
• A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.

  1985cited by this paper
• Validation of the tumor, nodes and metastasis classification of renal cell carcinoma.

  1985cited by this paper
• Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.

  1985cited by this paper
• Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report.

  1985cited by this paper
• Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.

  1985cited by this paper
• Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma.

  1985cited by this paper
• Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma.

  1985cited by this paper
• Interferon therapy in disseminated renal cell carcinoma.

  1985cited by this paper
• Human lymphoblastoid interferon therapy for advanced renal cell carcinoma.

  1984cited by this paper
• Interferon-alpha therapy of renal cancer.

  1984cited by this paper
• Current treatment of metastatic renal cell carcinoma with xenogeneic immune ribonucleic acid.

  1984cited by this paper
• The treatment of renal cell carcinoma with human leukocyte alpha-interferon.

  1983cited by this paper
• Treatment of advanced renal cell carcinoma--traditional methods and innovative approaches.

  1983cited by this paper
• Renal cell carcinoma: antitumor effects of leukocyte interferon.

  1983cited by this paper
• In vivo effect and parallel in vitro lymphocyte-mediated tumor cytolysis after Phase I xenogeneic immune RNA treatment of patients with widespread melanoma or metastatic renal cell carcinoma.

  1980cited by this paper
• Active specific immunotherapy of stage iv renal carcinoma with aggregated tumor antigen adjuvant

  1980cited by this paper
• Immune RNA Therapy for Renal Cell Carcinoma: Survival and Immunologic Monitoring

  1977cited by this paper
• Selective in vitro growth of T lymphocytes from normal human bone marrows.

  1976cited by this paper
• Immunotherapy for malignant lesions in man using immunogenic ribonucleic acid.

  1975cited by this paper
• Radical nephrectomy for renal cell carcinoma.

  1963cited by this paper

• Predicting the prognosis of patients with renal cell carcinoma based on systemic immune inflammatory index and prognostic nutritional index

  2025cites this paper
• Clinical Practice and Prognostic Molecular Biomarkers in Clear Cell Renal Cell Carcinoma: Latest Advancements

  2025cites this paper
• Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis

  2025cites this paper
• Core GRADE 5: rating certainty of evidence—assessing indirectness

  2025cites this paper
• RNA-Based Therapies in Kidney Diseases

  2025cites this paper
• Score pronostique « Pronopall » et immunothérapie, étude descriptive rétrospective

  2024cites this paper
• An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies.

  2023cites this paper
• CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma

  2023cites this paper
• FAP promotes clear cell renal cell carcinoma progression via activating the PI3K/AKT/mTOR signaling pathway

  2023cites this paper
• First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.

  2023cites this paper
• Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.

  2022cites this paper
• A Novel Cuprotosis-Related Gene FDX1 Signature for Overall Survival Prediction in Clear Cell Renal Cell Carcinoma Patients

  2022cites this paper
• Trastuzumab in combination with PEGylated interferon-α1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity.

  2022cites this paper
• Single-cell RNA-sequencing analysis reveals MYH9 promotes renal cell carcinoma development and sunitinib resistance via AKT signaling pathway

  2022cites this paper
• Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review

  2021cites this paper
• Total elbow arthroplasty for tumors of the distal humerus and elbow

  2021cites this paper
• Metastatic renal cell carcinoma complicated by right atrial thrombus

  2021cites this paper
• Comparison of reconstructive techniques following oncologic intraarticular resection of proximal humerus

  2020cites this paper
• Humeral stress shielding following cemented endoprosthetic reconstruction: An under‐reported complication?

  2020cites this paper
• Preoperative systemic immune-in ammation index predicts prognosis of patients with non-metastatic renal cell carcinoma: a propensity score-matched analysis

  2020cites this paper
• T‐cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications

  2020cites this paper
• Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials

  2020cites this paper
• Steroid receptor RNA activator inhibits the migration, invasion and stemness characteristics of renal cell carcinoma cells

  2020cites this paper
• The Immunotherapy Landscape in Renal Cell Carcinoma

  2020cites this paper
• Current and future aspect of immunotherapy for advanced renal cell carcinoma

  2020cites this paper
• Abundant CD8+ tumor infiltrating lymphocytes and beta-2-microglobulin are associated with better outcome and response to interleukin-2 therapy in advanced stage clear cell renal cell carcinoma.

  2020cites this paper
• Renal cell tumors convert natural killer cells to a proangiogenic phenotype

  2020cites this paper
• First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis

  2020cites this paper
• Cancer in Older Adults

  2019cites this paper
• Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

  2019cites this paper
• How does vaccine treatment compare with standard targeted therapy for first-line treatment of people with metastatic renal cell carcinoma?

  2019cites this paper
• How does targeted immunotherapy compare with standard targeted therapy for people with previously treated metastatic renal cell carcinoma?

  2019cites this paper
• Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials

  2019cites this paper
• Renal Cell Carcinoma: Recent Progress and Future Directions1

  2019cites this paper
• Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity

  2019cites this paper
• How does interferon-α (IFN-α), with or without standard targeted therapy, compare with standard targeted therapy for first-line treatment of people with metastatic renal cell carcinoma?

  2019cites this paper
• Urologic Malignancies

  2019cites this paper
• Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma

  2019cites this paper
• Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma

  2019cites this paper
• Immunotherapy for metastatic renal cell carcinoma: A systematic review

  2019cites this paper
• What are the effects of adding bevacizumab to interferon-α (IFN-α) for first-line treatment of people with metastatic renal cell carcinoma?

  2019cites this paper
• Prognostic value of B7-H1, B7-H3 and the stage, size, grade and necrosis (SSIGN) score in metastatic clear cell renal cell carcinoma

  2019cites this paper
• Clinical Efficacy and Complication Rate of Sunitinib 2/1 Versus 4/2 Schedule for the Treatment of Metastatic Renal Cell Cancer: A Systematic Review and Meta-Analysis.

  2019cites this paper
• Long Non-Coding RNA Emergence During Renal Cell Carcinoma Tumorigenesis

  2018cites this paper
• Metastases from Renal Cell Carcinoma. Recurrence Patterns, Detection and Management.

  2018cites this paper
• Cyanidin Curtails Renal Cell Carcinoma Tumorigenesis

  2018cites this paper
• Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC‐Registry

  2018cites this paper
• Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population

  2018cites this paper
• Renal cell carcinoma drug and cell therapy: today and tomorrow

  2018cites this paper
• Tumor Suppressor Gene P29ing4 is Overexpressed and Induces a CD8 T Effector Cell Response in Human Renal Cell Carcinoma

  2017cites this paper
• Targeted therapies for renal cell carcinoma

  2017cites this paper
• DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy

  2017cites this paper
• Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

  2017cites this paper
• Acupuncture as anticancer treatment?

  2017cites this paper
• Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.

  2017cites this paper
• Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy

  2017cites this paper
• Renal Cell Carcinoma : Recent Progress and Future Directions 1

  2017cites this paper
• Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications

  2017cites this paper
• Capsaicin mediates caspases activation and induces apoptosis through P38 and JNK MAPK pathways in human renal carcinoma

  2016cites this paper
• The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy

  2016cites this paper
• Establishment and characterization of a highly immunogenic human renal carcinoma cell line

  2016cites this paper
• Galangin inhibits cell invasion by suppressing the epithelial-mesenchymal transition and inducing apoptosis in renal cell carcinoma

  2016cites this paper
• Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma

  2016cites this paper
• Studies on renal progenitor cells and kidney cancer

  2016cites this paper
• Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer

  2016influential citation
• Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study.

  2016cites this paper
• Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma

  2016cites this paper
• Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma.

  2016cites this paper
• The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer

  2016cites this paper
• Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma

  2015cites this paper
• Applications of bacillus Calmette–Guerin and recombinant bacillus Calmette–Guerin in vaccine development and tumor immunotherapy

  2015cites this paper
• The T309G Murine Double Minute 2 Gene Polymorphism Is an Independent Prognostic Factor for Patients with Renal Cell Carcinoma

  2015cites this paper
• CANCER IMMUNOLOGY AND IMMUNOTHERAPY - UNDERSTANDING AND ADAPTATION THE CURRENT EVIDENCE TO OPTIMIZE PATIENT THERAPY OUTCOMES

  2015cites this paper
• Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma

  2015cites this paper
• Serum and Urine Biomarkers for Human Renal Cell Carcinoma

  2015cites this paper
• Therapeutic challenges in renal cell carcinoma.

  2015cites this paper
• Adjuvants and myeloid-derived suppressor cells: Enemies or allies in therapeutic cancer vaccination

  2014cites this paper
• Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases

  2014cites this paper
• Engrailed-2 is down-regulated but also ectopically expressed in clear cell renal cell carcinoma

  2014cites this paper
• Minimal changes in the systemic immune response after nephrectomy of localized renal masses.

  2014cites this paper
• Identification of an HLA-A2-Restricted Epitope Peptide Derived from Hypoxia-Inducible Protein 2 (HIG2)

  2014cites this paper
• Sequential therapy and prognostic factors in metastatic renal cell carcinoma: single centre experience.

  2014cites this paper
• miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma

  2014cites this paper
• Histopathological Aspects of Pancreatic Metastases in Renal Cell Carcinoma: Does the Mode of Invasion Permit Limited Resections?

  2014cites this paper
• Immunonkologisches Therapieprinzip beim Lungen- und Nierenzellkarzinom

  2014cites this paper
• Ancillary Diagnostic Techniques in the Evaluation of Adult Epithelial Renal Neoplasms: Indications, Caveats, and Pitfalls

  2014cites this paper
• Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre

  2014cites this paper
• Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinoma.

  2014cites this paper
• NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α.

  2014cites this paper
• Hypoxia‐induced downregulation of miR‐30c promotes epithelial‐mesenchymal transition in human renal cell carcinoma

  2013cites this paper
• A late recurrence of renal cell carcinoma as pancreatic metastases: a rare disease

  2013cites this paper
• Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Renal Cell Carcinoma

  2013cites this paper
• Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single‐center experience with 31 patients

  2013cites this paper
• Anti-CD70 Immunocytokines for Exploitation of Interferon-γ-Induced RIP1-Dependent Necrosis in Renal Cell Carcinoma

  2013cites this paper
• Comparison of vascular leak syndrome in mice treated with IL21 or IL2.

  2013cites this paper
• Interferon-γ-Induced Necrosis: An Antitumor Biotherapeutic Perspective

  2013cites this paper
• Tivozanib in the treatment of renal cell carcinoma

  2013cites this paper
• Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

  2013cites this paper
• Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon‐α

  2013cites this paper
• Renal Cell Carcinoma in Humans and Animals: A Brief Literature Review

  2013cites this paper